poisar

Stock

DiaMedica Therapeutics Inc. DMAC

$6.68-1.04%

Overview

DMAC market data

Price History

DMAC price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$0.70
Diluted earnings per share over the trailing twelve months.
Beta
0.97
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-1,146.8%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$4.63 – $10.42
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $360.8M · P/B 7.39.

Company News

7 captured
HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price TargetBenzinga · Aug 11, 2026, 3:02 PM
8-K filing — DiaMedica Therapeutics Inc. (DMAC)SEC EDGAR · Aug 10, 2026, 8:35 PM
DiaMedica Therapeutics Q2 EPS $(0.19) Beats $(0.20) EstimateBenzinga · Aug 10, 2026, 8:30 PM
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market SessionBenzinga · Jun 29, 2026, 12:15 PM
DiaMedica Therapeutics Doses First Patients In Its Phase 2 Trial Of DM199 For The Treatment Of Fetal Growth RestrictionBenzinga · Jun 23, 2026, 12:40 PM
DiaMedica Receives FDA Written Response About The Need For Additional Nonclinical Reproductive Toxicity Data To Support Continued Development Of DM199 For The Treatment Of PreeclampsiaBenzinga · Jun 16, 2026, 12:45 PM
DiaMedica Therapeutics Announces 75% Enrollment In Its Phase 2/3 ReMEDy2 trial of DM199 In Patients With Acute Ischemic StrokeBenzinga · May 20, 2026, 12:45 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock